Skip to search formSkip to main contentSkip to account menu

AMPD1 gene

Known as: AMPD1, skeletal muscle AMPD, AMP DEAMINASE 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Effects of AMPD1 gene C34T polymorphism on cardiac index, blood pressure and prognosis in patients with cardiovascular diseases: a meta-analysis
BackgroundThe meta-analysis was aimed to evaluate the effects of AMPD1 gene C34T polymorphism on cardiac function indexes, blood… 
2006
2006
Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients.
2005
2005
Myoadenylate deaminase deficiency
SummaryThis report concerns two unrelated males; one had sarcoidosis, sarcoid myopathy and muscle weakness, and the other had… 
2004
2004
AMPD1 (C34T) polymorphism and clinical outcomes in patients undergoing myocardial revascularization.
Review
2002
Review
2002
A G468-T AMPD1 mutant allele contributes to the high incidence of myoadenylate deaminase deficiency in the Caucasian population
2000
2000
First missense mutations (R388W and R425H) of AMPD1 accompanied with myopathy found in a Japanese patient
Skeletal muscle AMP deaminase (AMPD: E.C. 3.5.4.6) deficiency is one of the most common inherited defects in the Caucasians, but… 
1995
1995
Divergent N-terminal regions in AMP deaminase and isoform-specific catalytic properties of the enzyme.
AMP deaminase (AMPD) catalyzes the hydrolytic deamination of AMP to IMP and NH3. This activity is represented throughout… 
1993
1993
Functionally distinct elements are required for expression of the AMPD1 gene in myocytes
AMP deaminase (AMPD) is an enzyme found in all eukaryotic cells. Tissue-specific and stage-specific isoforms of this enzyme are… 
1991
1991
Receptor selectivity of cholecystokinin effects on mesoaccumbens dopamine neurons
Extracellular recording techniques were combined with antidromic stimulation to examine the effects of C‐terminal cholecystokinin… 
1984
1984
Human myoadenylate deaminase deficiency.
This entity was first described, in 5 patients, in 1978, as the consequence of the introduction of an effective histoenzymatic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)